In lung non-small cell lung cancer (NSCLC), the ctDNA determination of mutations of the epidermal growth factor receptor (EGFR) gene including the T790M-resistant allowed to selection the treatment between two drugs (erlotinib or osimertinib) [14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.